Roche and Spark Therapeutics’ road to a US$4.3 billion merger has been a rocky one, with various delays pushing the long-gestating agreement back four times. Now, in order to get all its regulatory ducks in a row, Roche is moving its own deal-close deadline back as well.
Roche moved its Spark closing deadline from January 31, 2020, to April 30, 2020, according to a Monday, July 8, regulatory filing. The move is a precautionary one, meant to give the deal partners time to clear any hurdles that may come up as US and UK antitrust regulators review the companies’ marriage.
In a note to Spark investors, Roche CEO Severin Schwan wrote that the plan was still to close the merger in 2019 despite the new deadline.
Full Content: Biopharma Dive
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 216.73.216.118
Please verify email or join us
to access premium content!
